Rare diseases
Investigational molecules
Locations
Recruiting trials first
25 clinical trials in this condition
Study of Pegozafermin Treatment for Patients with Liver Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)
BelgiumStudy on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)
BelgiumA Study Comparing Human Albumin and Saline Solution for Treating Kidney Injury in Patients with Advanced Liver Cirrhosis
SpainStudy on the Effect of Carvedilol for Patients with Cirrhotic Portal Hypertension
FranceIn short
Hepatic cirrhosis is permanent scarring of the liver that develops slowly over many years of continuous damage. Finding it early can be challenging because many people feel perfectly well until the disease has progressed significantly.
Many people living with cirrhosis have no idea their liver is damaged until the condition has advanced significantly. This is because the early stages often produce no noticeable symptoms. The liver is remarkably good at compensating for damage, continuing to function even when a significant portion of its tissue has been replaced by scar tissue. By the time symptoms appear, the disease may already be in a more serious stage.
Anyone who has risk factors for liver disease should consider getting tested, even if they feel completely healthy. If you regularly drink large amounts of alcohol—more than 50 units per week for men or 35 units per week for women—you have a higher chance of developing liver damage that could progress to cirrhosis. Similarly, people with chronic viral infections like hepatitis B (a viral infection that can become lifelong) or hepatitis C (a viral infection that often becomes chronic) should undergo regular liver assessments, as these infections can silently damage the liver over decades.
People living with obesity or type 2 diabetes are also at increased risk. These conditions can lead to excess fat accumulation in the liver, which, if left unmanaged, can cause inflammation and eventually scarring. Other groups who should seek diagnostic testing include those with autoimmune conditions affecting the liver, such as autoimmune hepatitis (when the immune system mistakenly attacks liver cells), primary biliary cholangitis, or primary sclerosing cholangitis. Genetic conditions like hemochromatosis (where the body stores too much iron), Wilson's disease (a disorder causing copper buildup), or alpha-1 antitrypsin deficiency can also damage the liver over time and require monitoring.
It is advisable to see a doctor if you notice any early warning signs, even if they seem minor. These might include feeling unusually tired all the time, losing your appetite without trying to diet, unexplained weight loss, nausea, or discomfort in the upper right side of your abdomen. Visible changes such as small spider-like blood vessels on your skin or redness on the palms of your hands can also be early clues. If you have any of these symptoms combined with known risk factors, it is important to seek medical advice promptly.
Diagnosing cirrhosis involves a combination of different approaches. Doctors use blood tests, imaging scans, and sometimes tissue samples to confirm the presence of liver scarring and to understand how severe the damage is. The process often begins with a conversation about your medical history and a physical examination, followed by more specific tests to get a clearer picture of your liver's condition.
Blood tests are usually the first step in diagnosing liver problems. These tests measure the levels of certain substances in your blood that can indicate how well your liver is working. One common group of tests looks at liver enzymes, which are proteins released when liver cells are damaged. Elevated levels can suggest ongoing liver injury. Blood tests also measure bilirubin, a yellow substance produced when red blood cells break down. When the liver is not functioning properly, bilirubin can build up, leading to jaundice—a yellowing of the skin and eyes.
Doctors may also check your blood's ability to clot by measuring proteins that the liver produces. If these clotting factors are low, it means the liver is not making enough of the proteins needed to stop bleeding. Another important blood test measures albumin, a protein made by the liver that helps keep fluid in your bloodstream. Low albumin levels can lead to fluid leaking into your abdomen or legs. Additionally, blood tests can look for signs of viral infections like hepatitis B or C, autoimmune disorders, or genetic conditions that might be causing liver damage.
Imaging tests allow doctors to see the structure of your liver without surgery. An ultrasound uses sound waves to create pictures of the liver and can show changes in its size, shape, or texture. It can also detect fluid buildup in the abdomen, which is a common complication of cirrhosis. Ultrasound is painless, widely available, and does not use radiation, making it a safe first choice for many patients.
A CT scan (computed tomography) provides more detailed images than an ultrasound. It uses X-rays taken from different angles and combines them with a computer to create cross-sectional pictures of the liver. CT scans can reveal the extent of scarring, detect tumors, and show blood vessel abnormalities that might result from cirrhosis. An MRI scan (magnetic resonance imaging) uses magnets and radio waves instead of radiation to produce highly detailed images. MRI is particularly good at identifying liver nodules and assessing the severity of fibrosis. Some specialized MRI techniques can even estimate the amount of scarring without needing a biopsy.
Another imaging test called transient elastography, also known as FibroScan, measures liver stiffness. This non-invasive test works like an ultrasound and provides an estimate of how much scar tissue is present. The stiffer the liver, the more advanced the scarring. This test is quick, painless, and increasingly used to monitor liver health over time.
A liver biopsy involves taking a small sample of liver tissue for examination under a microscope. This is considered the most accurate way to confirm cirrhosis and assess its severity. During the procedure, a thin needle is inserted through the skin into the liver to remove a tiny piece of tissue. The sample is then analyzed to see how much scarring is present and whether there are signs of inflammation or other damage.
While a biopsy provides valuable information, it is not always necessary. Doctors may decide to perform a biopsy if blood tests and imaging scans do not provide a clear diagnosis, or if they need to determine the exact cause of liver damage. The procedure carries a small risk of bleeding or infection, so it is typically reserved for cases where the information it provides will significantly change treatment decisions.
An endoscopy is a procedure used to look inside the digestive tract using a thin, flexible tube with a camera on the end. In patients with cirrhosis, doctors may perform an endoscopy to check for varices, which are enlarged veins in the esophagus (the tube connecting the throat to the stomach) or stomach. Varices develop when scarring in the liver blocks normal blood flow, causing blood to back up and find alternate routes. These veins can become fragile and may bleed, which is a serious and potentially life-threatening complication.
During the endoscopy, the doctor can see the size and appearance of any varices and assess the risk of bleeding. If varices are found, treatment such as banding (placing small rubber bands around the veins to stop them from bleeding) may be performed during the same procedure.
Cirrhosis must be distinguished from other liver conditions that cause similar symptoms. For example, fatty liver disease involves fat buildup in the liver but does not always lead to scarring. Blood tests and imaging can help differentiate between simple fat accumulation and more serious fibrosis. Acute liver injury from drug toxicity or sudden viral infection can cause liver enzymes to spike dramatically, but these conditions are usually reversible if caught early, unlike cirrhosis.
Doctors also need to rule out liver tumors, cysts, or abscesses, which can mimic some features of cirrhosis on imaging. A combination of tests—including blood work, scans, and sometimes a biopsy—helps doctors make an accurate diagnosis and plan the most appropriate treatment.
Clinical trials are research studies that test new treatments or approaches for managing cirrhosis and its complications. To join a clinical trial, patients must meet specific criteria to ensure the study results are reliable and that participants are safe. Diagnostic tests play a central role in determining whether someone is eligible for a trial and in monitoring their progress throughout the study.
Clinical trials typically require detailed baseline assessments before a patient can enroll. Blood tests are used to measure liver function, check for signs of infection, and assess overall health. Trials may require specific results, such as certain levels of liver enzymes, bilirubin, or albumin, to ensure participants have the right stage of disease for the study. Imaging tests like ultrasound, CT, or MRI scans may also be required to confirm the presence and extent of cirrhosis and to rule out other conditions that could interfere with the trial.
Many clinical trials use standardized scoring systems to classify the severity of cirrhosis. The Child-Pugh score is a common tool that assigns points based on five factors: bilirubin level, albumin level, blood clotting ability, presence of fluid in the abdomen, and degree of confusion or altered mental state. The total score places patients into one of three categories—A, B, or C—with A being the mildest and C the most severe. Trials often specify which category of patients they are studying.
Another widely used system is the MELD score (Model for End-Stage Liver Disease), which calculates a score based on blood tests measuring bilirubin, kidney function, and clotting ability. The MELD score predicts the risk of death within three months and is often used to prioritize patients for liver transplantation. Clinical trials may use the MELD score to select participants with a particular level of disease severity.
Some clinical trials focus on specific complications of cirrhosis, such as fluid buildup in the abdomen (ascites), confusion from liver dysfunction (hepatic encephalopathy), or bleeding from varices. To qualify for these trials, patients must undergo tests to confirm the presence and severity of the complication. For example, a trial studying treatments for ascites might require an ultrasound or CT scan to measure the amount of fluid in the abdomen. A trial for hepatic encephalopathy might include specialized cognitive tests or blood ammonia level measurements.
Once enrolled in a clinical trial, participants undergo regular diagnostic tests to monitor their response to the treatment being studied. These might include repeat blood tests, imaging scans, liver stiffness measurements, or endoscopies. The frequency and type of testing depend on the trial's design and goals. Careful monitoring ensures patient safety and helps researchers understand whether the new treatment is effective.
Participation in clinical trials can provide access to cutting-edge treatments that are not yet widely available. However, it is important to understand that not all experimental treatments will be effective, and some may have unknown risks. Patients considering a clinical trial should discuss the potential benefits and risks with their healthcare team and ensure they meet all the diagnostic criteria required for enrollment.
The outlook for someone with cirrhosis depends heavily on several factors, including the underlying cause of the liver damage, how early the condition is diagnosed, and whether the person can make lifestyle changes or receive treatment to slow its progression. In the early stages, called compensated cirrhosis, the liver can still perform most of its functions, and many people feel well and can live for many years without serious complications. However, as scarring increases and liver function declines, the condition progresses to decompensated cirrhosis, where complications such as fluid buildup, bleeding, confusion, and liver failure become more likely.
People who stop drinking alcohol, lose weight if they are overweight, manage diabetes and high blood pressure, and treat viral infections can significantly improve their prognosis. Stopping the cause of liver damage is the most important step in preventing further scarring. Those who develop complications such as ascites, variceal bleeding, or hepatic encephalopathy have a more serious prognosis and may need more intensive treatment, including consideration for liver transplantation.
Cirrhosis also increases the risk of developing liver cancer, particularly in people with chronic hepatitis B or C infections or those with long-term alcohol use. Regular monitoring with blood tests and imaging scans is important to detect cancer early, when treatment is more likely to be successful.
Survival rates for cirrhosis vary widely depending on the stage of disease at diagnosis. People with compensated cirrhosis generally have a much better outlook than those with decompensated cirrhosis. Studies show that individuals with compensated cirrhosis can live for many years, often a decade or more, especially if they address the underlying cause of liver damage. In contrast, those with decompensated cirrhosis have a much shorter life expectancy, often measured in months to a few years without a liver transplant.
The Child-Pugh score is often used to estimate survival. Patients with class A cirrhosis (the mildest form) have a relatively good prognosis, while those with class C cirrhosis (the most severe) have a much higher risk of death within one to two years. The MELD score is another tool that predicts three-month mortality. Higher MELD scores indicate a greater risk of death and are used to prioritize patients for liver transplantation.
Liver transplantation can dramatically improve survival for people with advanced cirrhosis. Many transplant recipients go on to live for many years after the procedure, with some studies showing five-year survival rates above 70 percent. However, not everyone is a candidate for transplantation, and access to donor organs can be limited.
It is important to remember that survival statistics are averages and do not predict the outcome for any individual person. Many factors, including age, overall health, response to treatment, and the presence of other medical conditions, influence how long someone with cirrhosis will live. Regular medical care, lifestyle changes, and close monitoring can all contribute to a better outcome.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Patient organisations offering help, community and advocacy
Tell us about your condition – we search every trial in Europe and connect you with the right site.
